Swiss natural beauty producer Weleda plans to expand its flagship Skin Food franchise into medical-grade skincare and daily personal care across global markets. The century-old product line generates approximately 20 per cent of Weleda’s global turnover, led by sales in Australia, Japan, the United States, and the United Kingdom.
First formulated in 1926 using chamomile, calendula, rosemary, and viola tricolor, the original multi-use cream remained unchanged for decades. The company has since adapted the blend into night creams, body oils, lip care, and face serums. A dedicated eye cream recently joined the range, with a hand wash and hand lotion scheduled to roll out in the first quarter of 2026.
New Categories and Clinical Formulations
Weleda is collaborating with professional makeup artists to refine formulas for high-definition photography and screen production. Beyond cosmetic skin prep, the group has initiated longer-term research and development targeting chronic dermatological conditions.
Over the next five to ten years, Weleda plans to test Skin Food formulations for acne, rosacea, eczema, and psoriasis. Jayn Sterland, Country Manager for the UK and Ireland, noted that product development will hinge on regulatory compliance across different jurisdictions. The company is also working on mineral UV protection formulations, though executives confirmed those products remain in testing.
Packaging Shifts and Digital Demand
Supply chain adjustments accompany the product rollout. Weleda has transitioned its packaging back to aluminium tubes, replacing temporary post-consumer recycled plastic with 100 per cent recycled aluminium worldwide.
In Asian retail channels, where multi-step skincare routines dominate department stores and specialty beauty chains, multi-purpose European heritage creams have found a distinct niche. While traditional drugstores stock the core green tubes, growth in Japan and Southeast Asia is shifting toward digital platforms. Social media campaigns on TikTok have drawn younger consumers who bypass brick-and-mortar shelves entirely.
Regulatory filings for the first wave of therapeutic claims across international beauty registries will determine how quickly Weleda can clear its clinical skincare line for retail distribution.














